Evidence map›Paper›PMID 38419461›Full record

SynthesisJournal of global health2024

Epidemiology and clinical features of SARS-CoV-2 infection in children and adolescents in the pre-Omicron era: A global systematic review and meta-analysis.

Durga Kulkarni, Nabihah Farhana Ismail, Fuyu Zhu, Xin Wang, Graciela Del Carmen Morales, Amit Srivastava, Kristen E Allen, Julia Spinardi, Ahmed Ehsanur Rahman, Moe H Kyaw and 1 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 5 countries.

Durga KulkarniCentre for Global Health, University of Edinburgh, Edinburgh, United Kingdom.
Nabihah Farhana IsmailCentre for Global Health, University of Edinburgh, Edinburgh, United Kingdom.
Fuyu ZhuSchol of Public Health, Nanjing Medical University, China.
Xin WangSchol of Public Health, Nanjing Medical University, China.
Graciela Del Carmen MoralesPfizer, Vaccines, Emerging Markets.
Amit SrivastavaPfizer, Vaccines, Emerging Markets.
Kristen E AllenPfizer, Vaccines, Emerging Markets.
Julia SpinardiPfizer, Vaccines, Emerging Markets.
Ahmed Ehsanur RahmanCentre for Global Health, University of Edinburgh, Edinburgh, United Kingdom.
Moe H KyawPfizer, Vaccines, Emerging Markets.
Harish NairCentre for Global Health, University of Edinburgh, Edinburgh, United Kingdom.
Pfizer (United States) · USNanjing Medical University · CNUniversity of Edinburgh · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Methods: We searched MEDLINE, Embase, Global Health, CINAHL, China National Knowledge Infrastructure, Wanfang, CQvip, and the World Health Organization (WHO) COVID-19 global literature databases for primary studies recruiting children aged ≤18 years with a diagnosis of SARS-CoV-2 infection confirmed either by molecular or antigen tests. We used the Joanna Briggs Institute critical appraisal tools to appraise the study quality and conducted meta-analyses using the random effects model for all outcomes except for race/ethnicity as risk factors of SARS-CoV-2 infection. Results: We included 237 studies, each reporting at least one of the study outcomes. Based on data from 117 studies, the pooled SARS-CoV-2 positivity rate was 9.30% (95% confidence interval (CI) = 7.15-11.73). Having a comorbidity was identified as a risk factor for SARS-CoV-2 infection (risk ratio (RR) = 1.33; 95% CI = 1.04-1.71) based on data from 49 studies. Most cases in this review presented with mild disease (n = 50; 52.47% (95% CI = 44.03-60.84)). However, 20.70% of paediatric SARS-CoV-2 infections were hospitalised (67 studies), 7.19% required oxygen support (57 studies), 4.26% required intensive care (93 studies), and 2.92% required assisted ventilation (63 studies). The case fatality ratio (n = 119) was 0.87% (95% CI = 0.54-1.28), which included in-hospital and out-of-hospital deaths. Conclusions: Our data showed that children were at risk for SARS-CoV-2 infections and severe outcomes in the pre-Omicron era. These findings underscore the need for effective vaccination strategies for the paediatric population to protect against the acute and long-term sequelae of COVID-19. Registration: PROSPERO: CRD42022327680.

Indexed as

COVID-19SARS-CoV-2AdolescentChildChild, PreschoolComorbidityGlobal HealthHumansInfantRisk Factors

Identifiers

PMID38419461
PMCPMC10902805
OpenAlexW4392285592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.